Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM-GUSTO: Anamorelin in Gastrectomized Gastric Cancer Patients Receiving Chemotherapy
jRCTs051210108Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anamorelin in gastric cancer (GC) and cancer anorexia-cachexia syndrome (CACS), sponsored by Ono Pharmaceutical. Primary endpoint: Changes of lean body mass. Started Nov 2021; status: completed.
02
Drugs
anamorelin
03
Conditions
gastric cancer (GC)cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on jRCTs051210108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210108.